RESEARCH ARTICLE

Effect of Parecoxib as an Adjunct to Patient-Controlled Epidural Analgesia after Abdominal Hysterectomy: A Multicenter, Randomized, Placebo-Controlled Trial

Wei-Feng Liu¹, Hai-Hua Shu¹, Guo-Dong Zhao², Shu-Ling Peng³, Jin-Fang Xiao⁴, Guan-Rong Zhang⁵, Ke-Xuan Liu¹ *, Wen-Qi Huang¹ *

¹ Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, ² Department of Anesthesiology, GuangDong General Hospital and GuangDong Academy of Medical Sciences, Guangzhou, China, ³ Department of Anesthesiology, The Second Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, ⁴ Department of Anesthesiology, NanFang Hospital, Guangzhou, China, ⁵ Health Management (Examination) Center, GuangDong General Hospital and GuangDong Academy of Medical Sciences, Guangzhou, China

* huangwenqi86@aliyun.com (WQH); liukexuan705@163.com (KXL)

Abstract

Objective

This multicenter, randomized, placebo-controlled study evaluated the efficacy and side effects of parecoxib during patient-controlled epidural analgesia (PCEA) after abdominal hysterectomy.

Methods

A total of 240 patients who were scheduled for elective abdominal hysterectomy under combined spinal-epidural anesthesia received PCEA plus postoperative intravenous parecoxib 40 mg or saline every 12 h for 48 h after an initial preoperative dose of parecoxib 40 mg or saline. An epidural loading dose of a mixture of 6 mL of 0.25% ropivacaine and 2 mg morphine was administered 30 min before the end of surgery, and PCEA was initiated using 1.25 mg/mL ropivacaine and 0.05 mg/mL morphine with a 2-mL/h background infusion and 2-mL bolus with a 15-min lockout. The primary end point of this study was the quantification of the PCEA-sparing effect of parecoxib.

Results

Demographic data were similar between the two groups. Patients in the parecoxib group received significantly fewer self-administered boluses (0 (0, 3) vs. 7 (2, 15), P < 0.001) and less epidural morphine (5.01 ± 0.44 vs. 5.95 ± 1.29 mg, P < 0.001) but experienced greater pain relief compared with the control group (P < 0.001). Patient global satisfaction was higher in the parecoxib group than the control group (P < 0.001). Length of hospitalization (9.50 ± 2.1, 95% CI 9.12~9.88 vs. 10.41 ± 2.6, 95% CI 9.95~10.87, P = 0.003) and
postoperative vomiting (17% vs. 29%, \( P < 0.05 \)) were also reduced in the parecoxib group. There were no serious adverse effects in either group.

**Conclusion**

Our data suggest that adjunctive parecoxib during PCEA following abdominal hysterectomy is safe and efficacious in reducing pain, requirements of epidural analgesics, and side effects.

**Trial Registration**

ClinicalTrials.gov (NCT01566669)

---

**Introduction**

Postoperative pain is one of the most important factors that prolongs time to recovery and delays discharge after surgery [1–3]. Patient-controlled epidural analgesia (PCEA) and patient-controlled intravenous analgesia (PCIA) offer good postoperative pain control [4]. Several randomized controlled trials demonstrated that patients treated with a combination of epidural opioids and local anesthetics exhibit improved pain scores and fewer side effects compared with patients treated with PCIA [5, 6]. Opioid therapy is recommended as a first-choice medication for postoperative pain management, but it is associated with several undesirable adverse effects, such as nausea, vomiting, sedation, and respiratory depression [7]. Acute pain service (APS) is important in the provision of effective pain relief and minimizing opioid-related side effects. The presence of APS, like in many other developing countries, is at a young stage in China [8]. Therefore, it is necessary to reduce the need for opioids during the postoperative period. Numerous studies demonstrated that multimodal therapy for postoperative analgesia has advantages over the use of opioids alone [9, 10]. The combination of nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids improved analgesia by inhibiting nociceptive impulses at central and peripheral sites of the pain transmission pathway and reduced the need for opioids during the postoperative period [11]. Selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) reduce postoperative pain without interfering with the normal mechanisms of platelet aggregation and hemostasis or increasing intraoperative blood loss. Therefore, these drugs may demonstrate a higher safety margin than non-selective NSAIDs [12–14].

Previous studies demonstrated that parecoxib sodium, a highly selective COX-2 inhibitor, is effective for the treatment of postoperative pain following various types of surgery [15–18]. Parecoxib was the first clinically available intravenous coxib with a greater analgesic efficacy that may produce synergistic effects with epidural opioids on postoperative pain relief. The present study investigated the effect of parecoxib as an adjuvant to a multimodal PCEA approach in patients undergoing gynecological surgery, with a hypothesis that parecoxib might reduce epidural morphine consumption (presented as a reduction in PCEA boluses).

**Materials and Methods**

**Study design and patient selection**

This multicenter, randomized, double-blinded, placebo-controlled trial adhered to the CONSORT guidelines for the reporting of randomized trial results [19] (S1 Checklist and S1 and S2 Protocols). The study was registered at ClinicalTrials.gov (NCT01566669) (Prior to the trial,
we read many research papers and found only a few trial registrations. Therefore, we didn't recognize the importance of pre-registering a trial on clinical trials site due to our limited knowledge. By 2012, we realized this problem and made an immediate compensation by registering this trial at ClinicalTrials.gov. Anyway, before and after registering, we're quite sure that the protocols of the trial and its conduction have not been modified. The authors confirm that all ongoing and related trials for this drug/intervention are registered. The Research Ethics Board at the First Affiliated Hospital, Sun Yat-sen University, approved this study (20090214, Guangzhou, China) on 12 March 2009. Women with an American Society of Anesthesiologists physical status class I–II, aged 18–64 years, who were undergoing abdominal hysterectomy (with or without oophorectomy) under combined spinal-epidural anesthesia (CSEA), were assessed for study eligibility. Patients were recruited on the day before surgery by a co-investigator. Written informed consent was obtained prior to the day of surgery. The study was conducted from June 2009 to May 2010 at four centers in Guangzhou, China (see Appendix).

The exclusion criteria included contraindications for CSE placement; known allergy, sensitivity, or contraindication to opioid and non-opioid analgesic drugs; history of bleeding disorders; peptic ulceration; or anticoagulant use within the past month; drug or alcohol abuse; current pregnancy or breastfeeding; and lack of ability to understand the use of pain assessment scales and the PCA device. Patients with asthma or bronchospasm who required treatment with glucocorticoids, poorly controlled hypertension or diabetes, a chronic or acute renal or hepatic disorder, or inflammatory bowel disease were also excluded. Patients were also excluded if they had used long-acting NSAIDs in the 4 days prior to the first dose of study medication or if they had taken antidepressants, narcotic analgesics, antihistamines, anxiolytics, hypnotics, sedatives, NSAIDs, or corticosteroids up to 24 h before administration of the study medication.

Randomization and masking

Eligible patients from each hospital were enrolled and received a sequential study number, which allocated them to one of the two study groups according to block randomization of a pre-assigned list. Randomization lists were generated using SAS software and consisted of assignments in blocks of four, with two patients in each block assigned to receive the study drug and the other two patients assigned to the control group. The allocation codes were maintained in pre-prepared opaque envelopes, which were used to label the drug packaging, and disclosed only after a patient was allocated to the next unique participation number. An independent statistician stored the randomization lists and envelopes. Participants, anesthesiologists, and observers were blinded to the treatment assignments. All statistical analyses were performed with masking maintained.

Study procedures

The patient was placed in the lateral position to receive the CSEA. The back was steriley prepared and draped, and 1% lidocaine was injected subcutaneously for local anesthesia into the lower lumbar vertebral interspace between L2 and L4. The anesthesiologist who performed the procedure chose the exact injection site after an examination of the patient's back.

The epidural space was identified using a loss of resistance technique with saline. A non-interlocking 25-gauge Whitacre spinal needle (Becton Dickinson Medical Devices Co. Ltd., Shanghai, China) was advanced through the Weiss needle using the needle-through-needle technique until the hubs touched to reach the subarachnoid space. The presence of spontaneous fluid returning to the spinal needle hub indicated the intrathecal space. The spinal component, which consisted of 10–15 mg of 0.5% or 0.75% hyperbaric bupivacaine, was infused into
the intrathecal space. The spinal needle was removed, and a 19-gauge, Flextip Plus™ (single open-ended hole) epidural catheter (Arrow International, Inc., USA) was inserted in a cephalad direction and secured with 4–5 cm remaining inside the epidural space. Any evidence of catheter entry into an epidural vein or cerebrospinal fluid excluded the patient from the study. No epidural medications were administered until 15 min after the spinal dose administration. A test dose of 2 mL of 2% lidocaine was administered via the epidural catheter after the initial 15-min period. If the spinal block proved insufficient for surgery, epidural 1% ropivacaine supplements (maximum of 8 mL) were administered as clinically indicated to maintain a T6 level of sensory blockade. Otherwise, the patient underwent general anesthesia and was excluded from the study.

Patients were randomized 1:1 to receive either 40 mg of parecoxib sodium (Pfizer Ltd, Pharmacia and Upjohn Company) (Group Parecoxib) IV or saline (Dazhong Pharmaceuticals Limited, China) (Group Control) at the same volume prior to the initial incision. Thereafter, patients in the parecoxib group received 40 mg of parecoxib IV every 12 h, and patients in the control group received 2 mL of saline every 12 h for 48 h. Post-anesthesia care unit nurses who were blinded to the study prepared the intervention drugs during the study. A mixture of 6 mL of 0.25% ropivacaine and 2 mg morphine was administered epidurally 30 min prior to the end of surgery. PCEA was initiated using 0.125% (1.25 mg/mL) ropivacaine and 0.005% (0.05 mg/mL) morphine with a basal infusion rate of 2 mL/h, a demand dose of 2 mL, and a 15-min lockout. Patients were instructed prior to surgery to use the PCEA mode at their discretion to maintain a numerical rating score (NRS) less than 3. Patients received 1 mg/kg of intravenous tramadol if the NRS was 4 or greater. Tropisetron (0.1 mg/kg) and dexamethasone (0.1 mg/kg) were routinely used for antiemetic prophylaxis 30 min before the end of surgery.

Primary and secondary outcome measures

The primary end point of this study was the quantification of the PCEA-sparing effect of a multimodal approach that contained parecoxib compared with a standard PCEA approach that did not contain parecoxib in patients undergoing abdominal hysterectomy. The number of PCEA bolus doses and total morphine consumption administered by the patient for 48 h postoperatively were recorded.

Secondary outcomes included pain intensity, the need for rescue analgesics, global satisfactory patient evaluation, and side effects, such as nausea, vomiting, pruritus, sedation, motor block in the lower extremities, and the time to the passage of flatus and the first bowel movement. Pain intensity was recorded on a 100-mm NRS ranging from 0 (no pain) to 100 (worst pain imaginable) and measured at rest and during activity. Pain during activity was elicited by asking the patient to take a deep breath followed by a forceful cough. A pain assessment was obtained immediately after the cough. A global satisfactory evaluation (using a 100-point scale from 1 = highly dissatisfied to 100 = highly satisfied) was obtained from the patient 48 h after skin closure. Assessment of sedation was performed using the Ramsay Sedation Scale (RSS). Motor block was assessed using a modified Bromage scale. Blood loss, length of hospitalization, and postoperative cardiovascular (CV) events were also recorded. The follow-up period was finished after the patient was discharged. Discharge was assessed by the surgeons according to the following discharge criteria: a) pain controlled with oral analgesics; b) stable vital signs; c) afebrile; d) passing flatus; e) incision clean, dry, and intact; and f) full diet tolerated. Pain scores, vital signs (measured using standard monitors during the first 24 h and a portable blood pressure monitor and pulse oximeter 36 h and 48 h after skin closure), the RSS, recovery of gastrointestinal function, and side effects were assessed at 4, 8, 12, 24, 36, and 48 h after skin closure by an investigator who was blinded to the treatment groups.
Blood test monitoring

Blood samples were drawn before and 48 h after surgery to determine liver (alanine amino-transferase and aspartate amino transferase) and renal (plasma creatinine and blood urea nitrogen concentration) function. Prothrombin time, active partial thromboplastin time, and international normalized ratio (INR) were also assessed.

Statistical analysis

The primary outcome of the study was PCEA-sparing effect of parecoxib. Coxibs purportedly reduced PCEA boluses in multimodal postoperative analgesia by approximately 32% [20]. We determined the sample size using information about expected reductions in the total self-administered PCEA boluses over 48 h, which was 16.25 ± 12.26 in a pilot observation study, and previous study [20]. These values were entered into the Stata program to calculate the sample size for a two-group trial, with a type-I error rate of 0.05. Accordingly, 100 subjects were required in each group to achieve 80% power to detect a reduction in PCEA boluses by 30%. Assuming a 20% dropout rate, the total number of participants was calculated as 240 (120 per group).

Statistical analyses were conducted on the intent-to-treat (ITT) population (all patients who were randomized and received at least one follow-up) and the efficacy-evaluable (EE) population (all patients who completed the full follow-up) using SPSS 19.0 software (SPSS, Chicago, IL, USA). Demographic and outcome data are presented as frequencies for categorical variables and means ± standard deviations (SD) or medians with quartiles for continuous variables according to patient distributions. Baseline data were analyzed using the t-test, Wilcoxon rank-sum test or chi-square test, as appropriate. General linear models were employed to estimate the mean differences between the parecoxib and placebo groups in medication use, adjusted for the clustering of participating centers. Least-squares means with 95% confidence intervals (CIs) were reported. To estimate mean changes in the NRS from baseline to follow-ups, linear mixed models for repeated measures were used, taking into account the correlations between individuals’ repeated measures over time. We also performed sensitivity analyses using the EE population approach to evaluate the impact of attrition after the exclusion of subjects with missing readings at the final follow-up. A P value less than 0.05 was considered statistically significant.

Results

Patient disposition and baseline characteristics

Patient recruitment commenced in June 2009 and concluded in May 2010. Two hundred and ninety four women were assessed for eligibility to enter the study. Fifty-four patients were not eligible or refused to participate in the initial phase of the trial. Therefore, 240 subjects remained, and consent was obtained. These subjects were enrolled and randomized to receive parecoxib (n = 120) or placebo (n = 120). Follow-up evaluations were incomplete in 15 patients (8 in the parecoxib group and 7 in the placebo group). Data from 4 of these patients (2 in each group) were excluded in the final statistical evaluation. Finally, a total of 236 patients were included in the ITT population (118 in each group), and a total of 225 patients were included in the EE population (112 in the parecoxib group and 113 in the placebo group). Fig 1 documents the patient flow throughout the trial.

The groups were comparable with respect to age, body mass index (BMI), ASA physical status, duration of surgery and anesthesia, fluid infusion, blood loss, urinary output, and ropivacaine supplement intake (Table 1). The distribution of each stratum in the two groups was similar.
Primary efficacy outcomes

PCEA requirements were significantly reduced in the parecoxib group at 48 h compared with the placebo group (Table 2). Patients who received parecoxib in the ITT population used a mean number of 2.0 PCEA boluses, and patients in the placebo group used a mean number of

Table 1. Demographic Data and Intraoperative Data.

| Item                        | Parecoxib Group (n = 118) | Control Group (n = 118) | P Value |
|-----------------------------|---------------------------|-------------------------|---------|
| Age (yr)                    | 42 ± 7                    | 42 ± 8                  |         |
| BMI (kg/m²)                 | 22.7 ± 2.6                | 22.3 ± 2.5              |         |
| Duration of anesthesia (min)| 131.8 ± 38.3              | 136.4 ± 41.0            |         |
| Duration of surgery (min)   | 107.7 ± 36.7              | 113.6 ± 42.4            |         |
| ASA physical status (I/II)  | 53/65                     | 51/67                   |         |
| Fluid infusion (mL)         | 1399 ± 249                | 1386 ± 222              | 0.669   |
| Intraoperative Blood loss (mL)| 76.7 ± 29.8              | 79.0 ± 30.0             | 0.557   |
| Urinary output (mL)         | 199.2 ± 86.9              | 205.9 ± 81.2            | 0.536   |
| Ropivacaine supplements [n (%)] | 10 (8.5)               | 9 (7.6)                 | 0.811   |

Data are expressed as means ± SD or counts. No significant differences were observed between the two groups. BMI = body mass index, ASA = American Society of Anesthesiologists.

doi:10.1371/journal.pone.0162589.t001
11.5 PCEA boluses, which represents an 83% reduction in PCEA bolus requirements and a 16% reduction in epidural morphine consumption among patients receiving parecoxib compared with those receiving the placebo ($P < 0.001$, Table 2).

### Secondary efficacy outcomes

The use of parecoxib was associated with significant reductions in pain scores compared with the placebo. NRSs were significantly greater at 4, 8, 12, 24, 36, and 48 h post-surgery in patients receiving placebo compared with parecoxib ($P < 0.001$) (Fig 2). Patients in the parecoxib group required less rescue analgesic tramadol (MD = -11.9%; 95% CI: -22.8--0.90%; $P = 0.021$) compared with the placebo group (Table 2). Patient satisfaction with their postoperative pain management was significantly higher at 48 h in the parecoxib group compared with the placebo group (100 (8) vs. 90 (8), $P < 0.001$).

### Side effects

Postoperative vomiting was significantly reduced in the parecoxib group. However, the groups were similar with respect to postoperative nausea, pruritus, and the time to the return of bowel function (Table 3). The length of hospitalization was significantly shorter in the parecoxib

### Table 2. PCEA Bolus Doses and Rescue Analgesics Administered over 48 h.

| Parameter                      | Parecoxib Group | Control Group | MD (95% CI)          | $P$ Value |
|-------------------------------|-----------------|---------------|----------------------|------------|
| ITT population                |                 |               |                      |            |
| No. of patients included in analysis | 118            | 118           |                      |            |
| PCEA demanded                 | 0 (0, 3)        | 7 (2, 15)     |                      | <0.001     |
| PCEA delivered                | 0 (0, 2)        | 5 (2, 11)     |                      | <0.001     |
| Total morphine consumption (mg) | 5.01 ± 0.44    | 5.95 ± 1.29   | -0.94 (-1.19, -0.70) * | <0.001     |
| Total ropivacaine consumption (mg) | 125.1 ± 11.1  | 148.7 ± 32.1  | -23.6 (-29.7, -17.4) * | <0.001     |
| Amount of tramadol            |                 |               |                      |            |
| 0 times                       | 96 (81.4)       | 82 (69.5)     |                      | 0.034<sup>a</sup> |
| 1 time                        | 20 (16.9)       | 32 (27.1)     |                      |            |
| 2 times                       | 2 (1.7)         | 4 (3.4)       |                      |            |
| Average tramadol consumption (mg) | 11.33 ± 24.80  | 18.60 ± 29.85 | -7.27 (-14.31, -0.23) * | 0.043      |
| EE population                 |                 |               |                      |            |
| No. of patients included in analysis | 112            | 113           |                      |            |
| PCEA demanded                 | 0 (0, 3)        | 8 (3, 15)     |                      | <0.001     |
| PCEA delivered                | 0 (0, 2)        | 6 (2, 11)     |                      | <0.001     |
| Total morphine consumption (mg) | 4.97 ± 0.33    | 5.68 ± 0.94   | -0.71 (-0.90, -0.53) * | <0.001     |
| Total ropivacaine consumption (mg) | 125.3 ±11.4  | 149.7 ±32.5   | -24.4 (-30.8, -18.0) * | <0.001     |
| Amount of tramadol            |                 |               |                      |            |
| 0 times                       | 90 (80.4)       | 78 (69.0)     |                      | 0.049<sup>a</sup> |
| 1 time                        | 20 (17.9)       | 31 (27.4)     |                      |            |
| 2 times                       | 2 (1.8)         | 4 (3.5)       |                      |            |
| Average tramadol consumption (mg) | 11.94 ± 25.32  | 18.98 ± 30.15 | -7.04 (-14.36, 0.28) * | 0.059      |

Data are expressed as means ± SD, medians (lower quartile, upper quartile), percentages (%), or MDs (95% CI).

* Analysis was performed with adjustment of participating centers using the general model.

<sup>a</sup> Comparison was performed using the Wilcoxon rank-sum test.

MD = mean difference; CI = confidence interval; PCEA = patient-controlled epidural analgesia; ITT = intent-to-treat; EE = efficacy evaluable.

doi:10.1371/journal.pone.0162589.t002
Fig 2. Postoperative numerical rating scores for pain assessments at rest (A) and during coughing (B) at different times after surgery. Patients scored pain using a NRS (0–100 mm, with 0 representing no pain and 100 mm representing the worst imaginable pain). Values are presented as means and 95% confidence interval. Lines extending above and below each plot represent the 95% confidence interval.

doi:10.1371/journal.pone.0162589.g002
group compared with the control group (9.50 ± 2.1, 95% CI 9.12~9.88 vs. 10.41 ± 2.6, 95% CI 9.95~10.87, P = 0.003).

Sedation scores (RSS) and modified Bromage scores were similar between the groups at all time points. Postoperative liver, renal, and coagulation functions did not differ significantly between the two treatment groups (Table 4). No patient in either group experienced wound or cardiovascular complications during hospitalization.

**Discussion**

This study demonstrated that the perioperative administration of parecoxib reduced the PCEA requirement, epidural morphine consumption, and postoperative vomiting and modestly reduced the length of hospital stay. Parecoxib also improved analgesic effects at rest and during cough and global satisfaction without side effects after abdominal hysterectomy.

CSEA is the most widely used technique for the management of gynecological anesthesia in China [21–23]. Previous studies demonstrated that neuraxial anesthesia exhibited beneficial effects via attenuation of the surgical stress response [24, 25] and postoperative analgesia [26] compared with parenteral opioids.

**Table 3. Postoperative Nausea and Vomiting, Pruritus, and Recovery Profiles.**

| Item                           | Parecoxib Group (n = 118) | Control Group (n = 118) | P Value |
|--------------------------------|----------------------------|-------------------------|---------|
| Postoperative nausea (n, %)    | 33 (28.0)                  | 46 (39.0)               | 0.073   |
| Postoperative vomiting (n, %)  | 20 (16.9)*                 | 34 (28.8)               | 0.030   |
| Pruritus (n, %)                | 28 (23.7)                  | 27 (22.9)               | 0.878   |
| Time to first flatus (h)       | 24 (12, 36)                | 36 (12, 36)             | 0.302   |
| Time to first bowel movement (h)| 48 (36, 60)                | 48 (24, 72)             | 0.641   |

Values are expressed as means ± SD, percentages (%), or medians (lower quartile, upper quartile).

*P < 0.05 compared with the placebo group. (actual P-values specified for all statistically significant variables).

doi:10.1371/journal.pone.0162589.t003

**Table 4. Postoperative Abnormal Clinical Laboratory Values.**

| Abnormal Values | Parecoxib Group (n = 112) | Control Group (n = 113) | P Value |
|-----------------|----------------------------|-------------------------|---------|
| ALT             | 10 (8.93%)                 | 8 (7.08%)               | 0.63    |
| AST             | 6 (5.36%)                  | 8 (7.08%)               | 0.78    |
| Cr              | 1 (0.89%)                  | 2 (1.77%)               | 1.0     |
| BUN             | 4 (3.57%)                  | 5 (4.42%)               | 1.0     |
| PT              | 5 (4.46%)                  | 3 (2.65%)               | 0.50    |
| APTT            | 0                          | 0                       | 1.0     |
| INR             | 0 (0.00%)                  | 1 (0.88%)               | 1.0     |

Data are expressed as percentages (%). No significant differences were observed between the two groups. ALT = alanine aminotransferase, AST = aspartate aminotransferase, Cr = creatinine, BUN = blood urea nitrogen, PT = prothrombin time, APTT = activated partial thromboplastin time, INR = international standard ratio.

doi:10.1371/journal.pone.0162589.t004
The epidural catheter was inserted between the L2 and L4 interspaces in this study, which were not located in the middle of the incision segments. Morphine is several-fold less lipophilic than other commonly used opioids, and it is less readily absorbed into the systemic circulation. Morphine is also more widely distributed within the intrathecal space, which provides a better selective spinal effect. A meta-analysis evaluated the efficacy of postoperative epidural analgesia, and epidural morphine was most commonly used (40%), followed by fentanyl (21%) and sufentanil (11%) [26]. Morphine is also the most commonly used epidural analgesic in our centers. Therefore, morphine was chosen as the principal component of the PCEA solution in our study. The recommended dose of epidural morphine is 0.1–1.0 mg/h, followed by a continuous infusion of 3–10 mL/h [27]. The present study used a small basal infusion dose of 0.1 mg/h to minimize side effects, and a low dose (2 mL/h) of the local anesthetic solution was used for additive analgesia.

The combination of NSAIDs and opioids effectively treats postoperative pain via the interruption of nociceptive impulses at central and peripheral sites of the pain transmission pathway, which reduces the need for opioids during the postoperative period [11]. Many studies demonstrated that parecoxib improves postoperative analgesia and decreases PCA opioid consumption by 30–63% following various types of surgery [16, 17, 28–30]. However, few studies evaluated coxibs as adjuvants to PCEA in postoperative pain management [20, 31]. Buvanendran et al. [20] reported that oral rofecoxib decreased PCEA (combination of bupivacaine and fentanyl) bolus doses by 32% in a randomized controlled trial assessing the effect of the perioperative administration of rofecoxib on opioid consumption and outcomes after total knee arthroplasty. Therefore, we speculated that parecoxib would also decrease PCEA bolus doses by 30%. The results of our study are consistent with those of a study by Buvanendran et al. [20]. The present study also revealed that parecoxib 40 mg/12 h was a useful adjuvant to epidural analgesia in patients undergoing gynecological surgery, which allowed a reduction of 83% in PCEA requirements (a reduction of 16% in epidural morphine consumption). The discrepancy between the effect observed by Buvanendran et al. [20], who demonstrated a 32% sparing effect in PCEA requirements, and the findings from this study may result from the various drugs and doses used and the different pathophysiological conditions. We consider the reduction in total morphine consumption (0.94 mg) by parecoxib as clinically relevant because pain scores were reduced, and it resulted in reduced postoperative vomiting and improved patient satisfaction.

Opioid-related side effects of perioperative coxibs are not certain [32]. Patients in the parecoxib group in the present study had an average discharge that was 0.9 days shorter than that of the control group. Better pain control, less morphine consumption, and less PONV may have led to the shorter stays in the parecoxib group. However, few studies reported that reduced hospitalization length was related to NSAIDs [33]. In our study, the length of hospital stay is much longer in both groups compared with other reports [34]. The difference between the greater effect observed in the present study is associated not only with the medical condition but also with the different medical system in China, where patients are hospitalized for preoperative evaluation about 3 days before the operation. Future trials are needed to clarify the effect of coxibs on reductions in hospitalization lengths using a cost-effect analysis.

Apfel et al. [35] showed that the incidence of opioid-induced postoperative nausea and vomiting (PONV) in females was above 40%, and PONV influenced global evaluation ratings. We documented a 41% reduction in vomiting in the parecoxib group with no significant difference in nausea, in contrast to the findings of White et al. [36]. Inoue et al. [37] reported that the incidences of nausea and vomiting were 60% and 35%, respectively, in a study comparing the analgesic efficacy of a morphine and ropivacaine combination for PCEA following gynecological surgery. The routine administration of tropisetron and dexamethasone for antiemetic
prophylaxis, avoidance of opioids during the maintenance of anesthesia, and the lower use of epidural morphine and intravenous tramadol clearly contributed to the low incidence of postoperative emetic symptoms in the present study.

Previous studies demonstrated that many conventional preoperative non-selective COX inhibitors increase the risk of perioperative bleeding [38, 39]. Conventional non-selective COX inhibitors interfere with platelet function, but selective COX-2 inhibitors do not affect platelet aggregation or increase intraoperative blood loss [24, 40, 41]. Our data are consistent with these findings because the perioperative administration of 40 mg parecoxib had no significant effects on coagulation function or blood loss, which is consistent with the findings that parecoxib exerts a minimal effect on serum thromboxane and platelet function [13, 41, 42]. However, a significant decrease in hemoglobin concentration during the first 24 hours following skin closure associated with parecoxib (4.3 g·dL\(^{-1}\)(3.6/4.9) vs. 3.2 g·dL\(^{-1}\)(2.4/5.0)) has been recently reported, while lack of statistical significance in intraoperative blood loss and the total blood loss at 48 hours postoperatively between both groups [43]. An increased incidence of postoperative anemia but lack of statistical significance associated with parecoxib (14.1% vs. 10%) has also been previously reported [44]. Therefore, the effects of selective COX-2 inhibitors on blood loss should be further demonstrated in future trials.

Non-selective NSAIDs inhibit COX-1 and COX-2, which are isoenzymes that are involved in prostaglandin synthesis. The anti-inflammatory effects of non-selective NSAIDs result from the inhibition of COX-2, whereas the harmful gastrointestinal effects of NSAIDs are mediated primarily through the inhibition of COX-1 [45]. Several prospective clinical trials suggested that selective COX-2 inhibitors may be associated with better gastrointestinal tolerance and comparable CV events [46, 47]. Nussmeier et al. [17] demonstrated more comparable upper gastrointestinal and CV events with parecoxib and valdecoxib compared with placebo. This study also revealed no differences in gastrointestinal function and CV events. However, there may be no differences in the incidence of serious vascular events between coxibs and conventional non-selective NSAIDs [48]. Nevertheless, these side effects may not be problematic with the short-term administration of parecoxib to patients with normal renal function and without CV risk factors, as shown in our study.

The limitations of our study include the exclusion of faster-onset opioids (e.g., hydromorphone) in PCEA administration, which are not available in most hospitals in China. Morphine remains the most widely used opioid for pain management because of their advantages of prolonged duration, high analgesic potency, and extended dermatomal level activity. The current study can also be criticized because of the failure to include an active comparable NSAID (e.g., flurbiprofen) or a different type of non-opioid analgesic. Future studies should compare parecoxib with non-selective NSAIDs or a different type of non-opioid analgesic in combination with morphine PCEA after surgery. Thirdly, the study was designed to assess side effects as a secondary outcome measure, and originally powered based on the expected PCEA-sparing effect. Therefore, the sample size may be insufficient to really evaluate risks. Finally, we failed to administer different doses of morphine or parecoxib and examine a dose-response effect. Further trials are required to demonstrate a dose-effect relationship between parecoxib and morphine PCEA.

**Conclusion**

The IV administration of parecoxib (40 mg q12 h for 48 h) is an effective adjuvant to epidural analgesia that combines local anesthetic and morphine after gynecological surgery. The short-term use of parecoxib decreased the requirement for epidural morphine, reduced pain scores, resulted in better patient satisfaction, and modestly reduced the length of stay.
Appendix

Investigators
Wei-Feng Liu, PhD., M.D., Hai-Hua Shu, PhD. M.D., Ke-Xuan Liu, PhD., M.D., Wen-Qi Huang, M.D., Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (60 patients); Guo-Dong Zhao, M.D., Department of Anesthesiology, GuangDong General Hospital, Guangzhou, China (60 patients); Jin-Fang Xiao, M.D., Department of Anesthesiology, NanFang Hospital, Guangzhou, China (60 patients); Shu-Ling Peng, PhD., M.D., Department of Anesthesiology, The Second Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (60 patients).

Supporting Information
S1 Checklist. CONSORT 2010.
(DOC)
S1 Protocol. English copy of trial protocol.
(DOC)
S2 Protocol. Trial Protocol in Chinese submitted to the hospital ethical committee.
(DOC)

Acknowledgments
The authors sincerely thank the patients who participated in this study and the staff involved in this work.

Author Contributions
Conceived and designed the experiments: WFL GDZ SLP JFX KXL WQH.
Performed the experiments: WFL GDZ SLP JFX KXL WQH.
Analyzed the data: WFL HHS GRZ KXL WQH.
Contributed reagents/materials/analysis tools: GRZ.
Wrote the paper: WFL KXL WQH.

References
1. Yeh CC, Jao SW, Huh BK, Wong CS, Yang CP, White WD, et al. Preincisional dextromethorphan combined with thoracic epidural anesthesia and analgesia improves postoperative pain and bowel function in patients undergoing colonic surgery. Anesth Analg. 2005; 100:1384–9. PMID: 15845691.
2. Horlocker TT, Kopp SL, Pagnano MW, Hebl JR. Analgesia for total hip and knee arthroplasty: A multimodal pathway featuring peripheral nerve block. J Am Acad Orthop Surg. 2006; 14:126–35. PMID: 16520363.
3. Ashburn MA, Caplan RA, Carr DB, Connis RT, Ginsberg B, Green CR, et al. Practice Guidelines for Acute Pain Management in the Perioperative Setting: An Updated Report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012; 116:248–73. PMID: 22227789. doi: 10.1097/ALN.0b013e31829c1930.
4. Alon E, Jaquenod M, Schaeppi B. Post-operative epidural versus intravenous patient-controlled analgesia. Minerva Anestesiol. 2003; 69:443–6. PMID: 12768181.
5. Rigg JR, Jamrozik K, Myles PS, Silberst B, Peyton PJ, Parsons RW, et al. Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial. Lancet. 2002; 359:1276–82. PMID: 11985272.
6. Ferguson SE, Mahotra T, Seshan VE, Levine DA, Sonoda Y, Chi DS, et al. A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery. Gynecol Oncol. 2009; 114:111–6. doi: 10.1016/j.ygyno.2009.03.014. Epub 2009/04/23. PMID: 19395071.

7. Marret E, Kurdi O, Zufferey P, Bonnet F. Effect of nonsteroidal antiinflammatory drugs on patients controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology. 2005; 102:1249–60. PMID: 15915040.

8. Govind P, Bhakta P, Dureja GP, Gupta A, Venkataramu A. Acute pain service: the journey in a developing country setting. Acta Anaesthesiol Scand. 2015; 59:98–106. doi: 10.1111/aas.12434. Epub 2014 Oct 28. PMID: 25349071.

9. Kehlet H, Dahl JB. The value of multimodal or balanced analgesia in postoperative pain treatment. Anesth Analg. 1993; 77:1048–56. PMID: 8105724.

10. Nong L, Sun Y, Tian Y, Li H, Li H. Effects of parecoxib on morphine analgesia after gynecologic tumor operation: a randomized trial of parecoxib used in postsurgical pain management. J Surg Res. 2013; 183:821–6. doi: 10.1016/j.jss.2013.02.059. Epub 2013/03/30. PMID: 23587455.

11. Grass JA, Sakima NT, Valley M, Fischer K, Jackson C, Walsh P, et al. Assessment of ketorolac as an adjuvant to fentanyl patient-controlled epidural analgesia after radical retropubic prostatectomy. Anesthesiology. 1993; 78:642–8. PMID: 8466063.

12. Joshi GP, Viscusi ER, Gan TJ, Minkowitz H, Cippolle M, Schuller R, et al. Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Anesth Analg. 2004; 98:336–42. PMID: 14742366.

13. Graff J, Arabmotlagh M, Cheung R, Geisslinger G, Harder S. Effects of parecoxib and dipyrone on platelet aggregation in patients undergoing meniscectomy: a double-blind, randomized, parallel-group study. Clin Ther. 2007; 29:438–47. PMID: 17577465.

14. Joshi W, Connelly NR, Reuben SS, Wolkenhaar M, Thakkar N. An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. Anesth Analg. 2003; 97:35–8. PMID: 12818939.

15. Neuss H, Koplin G, Haase O, Reetz C, Mall JW. Preemptive analgesia reduces pain after radical axillary lymph node dissection. J Surg Res. 2010; 162:88–94. doi: 10.1016/j.jss.2009.01.029. Epub 2009/02/21. PMID: 19524262.

16. Ng A, Temple A, Smith G, Emembolu J. Early analgesic effects of parecoxib versus ketorolac following laparoscopic sterilization: a randomized controlled trial. Br J Anaesth. 2004; 92:846–9. Epub 2004/04/30. PMID: 15121727.

17. Nussmeier NA, Whelton AA, Brown MT, Joshi GP, Langford RM, Singla NK, et al. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology. 2006; 104:518–26. PMID: 16508400.

18. Vadalouca A, Moka E, Chatzidimitriou A, Siafaka I, Sikoli P, Argyra E. A randomized, double-blind, placebo-controlled study of preemptively administered intravenous parecoxib: effect on anxiety levels and procedural pain during epidural catheter placement for surgical operations or for chronic pain therapy. Pain Pract. 2009; 9:181–94. doi: 10.1111/j.1533-2500.2009.00271.x. Epub 2009/03/03. PMID: 19298364.

19. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet. 2001; 357:1191–4. doi: 11323066.

20. Buvanendran A, Kroin JS, Tuman KJ, Lubenow TR, Elmofty D, Moric M, et al. Effects of perioperative administration of a selective cyclooxygenase-2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial. JAMA. 2003; 290:2411–8. PMID: 14612477.

21. Han G, Zhao GY, Li L, Zhao P. Comparison of hemodynamics after combined spinal-epidural anaesthesia between decubitus and sitting positions in aged patients undergoing total hip replacement. Anesthesiology. 2014; 120:193–6. doi: 10.1153/000362214. Epub 2014 May 23. PMID: 24861192.

22. Zhang XY, Fan Y, Manyande A, Tian YK, Yin P. Effects of music on target-controlled infusion of propofol requirements during combined spinal-epidural anaesthesia. Anaesthesia. 2005; 60:990–4. PMID: 16178044.

23. Wang X, Xu JM, Zhou F, He L, Cui YL, Li ZJ. Maternal Position and Development of Hypotension in Patients undergoing Cesarean Section under Combined Spinal-Epidural Anaesthesia of Intrathecal Hyperbaric Ropivacaine. Med Sci Monit. 2015; 21:52–8. doi: 10.1269/000362214. Epub 2014 May 23. PMID: 2557016.

24. Rigg JRA. Does regional block improve outcome after surgery? Anaesth Intensive Care. 1991; 19:404–11. PMID: 1767911.
25. Liu S, Carpenter RL, Neal JM. Epidural anesthesia and analgesia: their role in postoperative outcome. Anesthesiology. 1995; 82:1474–506. PMID: 7793661.

26. Block BM, Liu SS, Rowlingson AJ, Cowan AR, Cowan JA Jr, Wu CL. Efficacy of postoperative epidural analgesia: a metaanalysis. JAMA. 2003; 290:2455–63. PMID: 14612482.

27. Cousins MJ, Mather LE. Intrathecal and epidural administration of opioids. Anesthesiology. 1984; 61:276–310. PMID: 620753.

28. Nirthisard S, Werawataganon T, Bunburaphong M, Wongsakornchaikul C, Tolek K. Improving the Analgesic Efficacy of Intrathecal Morphine with Parecoxib After Total Abdominal Hysterectomy. Anesth Analg. 2007; 105:822–4. PMID: 17717245.

29. Tang J, Li S, White PF, Chen X, Wender RH, Quon R, et al. Effect of parecoxib, a novel intravenous cyclooxygenase-type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology. 2002; 96:1305–9. PMID: 12170040.

30. Wu Xin-min, Yue Yun, Zhang Liping, Wang Jun-ke, Ai Deng-bing, Yu Bu-wei, et al. Morphine-sparing effect and safety of parecoxib for postoperative analgesia. Chin J Anesthesiol. 2007; 27:8–10.

31. Senard M, Deflandre EP, Ledoux D, Roediger L, Hubert BM, Radermeker M, et al. Effect of celecoxib combined with thoracic epidural analgesia on pain after thoracotomy. Br J Anaesth. 2010; 105:196–200. doi: 10.1093/bja/aeq129. Epub 2010/08/25. PMID: 20581214.

32. Elia N, Lysakowski C, Tramèr MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology. 2005; 103:1296–1304. PMID: 16306743.

33. Bainbridge D, Cheng DC, Martin JE, Novick R. NSAID-analgesia, pain control and morbidity in cardiothoracic surgery. Can J Anaesth. 2006; 53:46–59. PMID: 16371609.

34. Woelk JL, Borah BJ, Trabuco EC, Heien HC, Gebhart JB. Cost differences among robotic, vaginal, and abdominal hysterectomy. Obstet Gynecol. 2014; 123:255–62. PMID: 24402586. doi: 10.1097/AOG.0000000000000090

35. Apfel CC, Larra E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999; 91:693–700. PMID: 10485781.

36. White PF, Sacan O, Tufanogullari B, Eng M, Nuangchamnong N, Ogunnaike B. Effect of short-term postoperative celecoxib administration on patient outcome after outpatient laparoscopic surgery. Can J Anaesth. 2006; 53:46–59. PMID: 16371609.

37. Inoue S, Kawakami T, Seo N. A comparison of morphine concentrations for patient-controlled epidural analgesia following gynecological surgery. Minerva Anestesiol. 2009; 75:498–503. Epub 2009/05/21. PMID: 19461562.

38. Marret E, Flahault A, Samama CM, Bonnet F. Effects of postoperative, nonsteroidal, antiinflammatory drugs on bleeding risk after tonsillecctomy: meta-analysis of randomized, controlled trials. Anesthesiology. 2003; 8:1497–1502. PMID: 12766664.

39. Bugter ML, Dirksen R, Jhamandas K, Slappendel R, Weber EW, Mline B. Prior ibuprofen exposure does not augment opioid drug potency or modify opioid requirements for pain inhibition in total hip surgery. Can J Anaesth. 2003; 50:445–9. PMID: 12734151.

40. Silverman DG, Halaszynski T, Sinatra R, Rinder CS. Rofecoxib does not compromise platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol. 2003; 43:504–13. PMID: 12751271.

41. Dirkmann D, Groeben H, Farhan H, Stahl DL, Eikermann M. Effects of parecoxib on anagelseia benefit and blood loss following open prostatectomy: a multicentre randomized trial. BMC Anesthesiol. 2015; 15:31. doi: 10.1186/s12871-015-0015-y. eCollection 2015. PMID: 25767411.

42. Malan TP Jr, Marsh G, Hakki SI, Grossman E, Traylor L, Hubbard RG. Parecoxib sodium, a parenteral cyclooxygenase-2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology. 2003; 98:950–8. PMID: 12657858.

43. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999; 22:96:7563–8. PMID: 10377455.
46. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343:1520–8. PMID: 11087881.

47. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284:1247–5. PMID: 10979111.

48. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ. 2006; 332:1302–8. PMID: 16740558.